Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CLEVIPREX vs CALAN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.
Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.
For the reduction of blood pressure when oral therapy is not feasible or desirable,For the management of perioperative hypertension
Angina pectoris (chronic stable, vasospastic, unstable),Essential hypertension,Supraventricular tachyarrhythmias (e.g., atrial fibrillation, atrial flutter, PSVT)
Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.
Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.
Terminal elimination half-life: 2.7 minutes (dihydropyridine ring reduction) and 15 minutes (ester hydrolysis); clinical context: rapid offset allows precise titration
Terminal elimination half-life is 3-7 hours for immediate-release; can be prolonged to 12-16 hours with sustained-release due to slow absorption; increased in hepatic impairment.
Rapidly metabolized by esterases in the blood and extravascular tissues to an inactive carboxylic acid metabolite (H152/81). Not primarily dependent on hepatic CYP450 enzymes.
Extensively metabolized in the liver via CYP3A4, CYP1A2, and CYP2C8 isoenzymes; undergoes N-dealkylation and O-demethylation; first-pass metabolism results in low bioavailability (20-35%).
Renal: 63–73% as metabolites, fecal: 7–10%, unchanged drug in urine: <1%
Approximately 70% renal (3-4% unchanged, remainder as metabolites) and 25% biliary/fecal.
87–97% bound to plasma proteins (primarily albumin)
Approximately 90% bound to plasma proteins, primarily albumin.
0.32 L/kg (approx. 22 L for 70 kg); indicates limited extravascular distribution
Vd 4-5 L/kg; indicates extensive tissue distribution beyond plasma volume.
Intravenous: 100% (only route administered)
Oral bioavailability is 20-35% due to extensive first-pass hepatic metabolism; IV bioavailability is 100%.
No dose adjustment required for renal impairment. Clevidipine is not removed by dialysis.
Cr Cl <30 m L/min: reduce dose by 50% and monitor carefully.
Contraindicated in patients with severe hepatic impairment (Child-Pugh Class C). Use with caution in moderate impairment (Child-Pugh B); consider lower initial doses and titrate slowly.
Child-Pugh A: 50% of normal dose; Child-Pugh B: 25% of normal dose; Child-Pugh C: contraindicated or use with extreme caution.
Safety and efficacy not established in pediatric patients. No FDA-approved dosing recommendations.
Oral: 4-8 mg/kg/day in 3 divided doses; IV: 0.1-0.3 mg/kg over 2 minutes, max 5 mg.
No specific dose adjustment required. Elderly patients may be more sensitive to hypotensive effects; use lower initial doses and titrate cautiously.
Start at lowest dose (e.g., 40 mg 3 times daily) and titrate slowly; monitor for hypotension and bradycardia.
None.
Contains verapamil hydrochloride. Risk of serious adverse effects including hypotension, bradycardia, AV block, and cardiac arrest. Must not be administered to patients with severe left ventricular dysfunction, cardiogenic shock, or sick sinus syndrome (unless paced).
Use caution in patients with heart failure, as beta-blocker withdrawal may exacerbate angina; continue beta-blocker therapy.,Hypotension and reflex tachycardia may occur; monitor blood pressure and heart rate closely.,Can cause acute kidney injury or worsening of renal function in at-risk patients.,Lipid emulsion formulation; use caution in patients with severe hypertriglyceridemia or lipid metabolism disorders.,Contains soybean oil and egg lecithin; contraindicated in patients with allergies to soybeans or eggs.,Not recommended for use in pediatric patients due to lack of safety and efficacy data.
May cause hypotension, bradycardia, AV block, and exacerbation of heart failure. Avoid in patients with pre-existing conduction abnormalities. Use caution with beta-blockers, digoxin, and CYP3A4 inhibitors. Abrupt withdrawal may exacerbate angina. May increase lithium and carbamazepine levels.
Hypersensitivity to clevidipine or any component of the formulation (including soybean oil or egg lecithin),Severe aortic stenosis (may reduce cardiac output and worsen symptoms),Patients with defective lipid metabolism (e.g., hyperlipoproteinemia, lipoid nephrosis, acute pancreatitis with hyperlipidemia)
Severe left ventricular dysfunction, cardiogenic shock, sick sinus syndrome (without pacemaker), second- or third-degree AV block (without pacemaker), atrial flutter/fibrillation with accessory bypass tract (e.g., WPW syndrome), concurrent use of IV beta-blockers.
No specific food interactions; administer IV only. The lipid emulsion contains soybean oil and egg lecithin; contraindicated in patients with allergies to soy or eggs. No oral intake required.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4 metabolism, increasing verapamil levels and risk of toxicity. Limit alcohol intake as it may enhance hypotensive effects. High-fat meals may delay absorption but not extent; take consistently with regard to meals.
Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinically relevant doses. However, maternal toxicity at high doses led to fetal effects (reduced fetal weight, delayed ossification). First trimester: limited data; risk cannot be excluded. Second and third trimesters: may cause fetal acidosis, hypotension, and bradycardia due to maternal hypotension. Use only if potential benefit justifies potential risk.
First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal bradycardia, hypotension, and impaired placental perfusion; avoid use for pregnancy-induced hypertension due to risk of fetal hypoxia.
No data on presence in human milk or effects on breastfed infants. Clevidipine is highly protein-bound (>99%) and rapidly metabolized, suggesting minimal excretion into milk. However, caution is advised. M/P ratio: not determined.
Verapamil (CALAN) is excreted into breast milk; M/P ratio approximately 0.6. The relative infant dose is low (estimated <5% of maternal weight-adjusted dose). No adverse effects reported in breastfed infants. Caution in preterm infants or those with renal impairment.
No specific dose adjustments studied in pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered metabolism) may affect clearance, but no data. Use lowest effective dose and shortest duration. Titrate to effect with caution, as pregnant patients may have increased sensitivity to hypotensive effects.
Pregnancy may increase clearance of verapamil; monitoring of therapeutic effect advised. Dose may need adjustment based on clinical response. Avoid use in pregnancy-induced hypertension.
CLEVIPREX (clevidipine) is an ultrashort-acting dihydropyridine calcium channel blocker for IV use in perioperative hypertension. Onset within 2-4 minutes, half-life ~1 minute. Titrate every 5-10 minutes; avoid in severe aortic stenosis, heart failure with reduced ejection fraction, and lipid disorders (formulated in lipid emulsion). Monitor for reflex tachycardia. Use aseptic technique; discard unused portion after 12 hours.
Calan (verapamil) is a class IV antiarrhythmic and calcium channel blocker. Use caution in patients with hepatic impairment due to reduced clearance; dose adjustment may be needed. Avoid in patients with pre-existing bradycardia, second- or third-degree AV block, or sick sinus syndrome unless a pacemaker is present. May increase digoxin levels; monitor digoxin concentrations. Use with caution in patients with hypertrophic cardiomyopathy. For IV administration, have calcium gluconate available to reverse hypotension or bradycardia. Not recommended for use in acute myocardial infarction or cardiogenic shock.
This medication is given intravenously to rapidly lower blood pressure during surgery or in hospital settings.,You will be closely monitored for heart rate and blood pressure changes during infusion.,Report any symptoms like chest pain, shortness of breath, or irregular heartbeat immediately.,Do not stop or adjust the infusion on your own; it is controlled by healthcare staff.,Inform your doctor if you have any allergies to eggs, soybeans, or lipids.
Take exactly as prescribed; do not skip doses or stop abruptly without consulting your doctor.,Avoid grapefruit juice as it can increase verapamil levels and risk of side effects.,If you miss a dose, take it as soon as you remember unless it is almost time for the next dose; do not double the dose.,Avoid alcohol as it may worsen side effects like dizziness or low blood pressure.,Report symptoms of bradycardia (slow heart rate), palpitations, shortness of breath, or swelling of ankles/feet.,This medication may cause dizziness; avoid driving or operating machinery until you know how it affects you.,Do not consume grapefruit or its juice during treatment.,Keep a regular medication schedule and do not change brands without doctor approval.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CLEVIPREX vs CALAN, answered by our medical review team.
CLEVIPREX is a Calcium Channel Blocker that works by Cleviprex (clevidipine) is a dihydropyridine L-type calcium channel blocker with high vascular selectivity. It inhibits calcium influx into vascular smooth muscle cells, causing arterial vasodilation and reduced peripheral vascular resistance.. CALAN is a Calcium Channel Blocker that works by Verapamil inhibits calcium ion influx through voltage-gated L-type calcium channels in cardiac and vascular smooth muscle, leading to decreased myocardial contractility, slowed AV conduction, and vasodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CLEVIPREX and CALAN depend on the specific clinical indication. These are both Calcium Channel Blocker agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CLEVIPREX is: Initiate intravenous infusion at 1-2 mg/kg/hr, titrate by 0.5-1 mg/kg/hr every 90 minutes up to maximum 32 mg/kg/hr. Maintenance dose: 4-6 mg/kg/hr. Route: IV. Frequency: continuous infusion.. The standard adult dose of CALAN is: Initial: 80-120 mg orally 3 times daily; maintenance: 240-480 mg/day in 3-4 divided doses. IV: 5-10 mg over 2 minutes, may repeat after 15-30 minutes.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CLEVIPREX and CALAN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CLEVIPREX is classified as Category C. Cleviprex (clevidipine) is a calcium channel blocker. No adequate and well-controlled studies in pregnant women. In animal studies, no teratogenic effects were observed at clinical. CALAN is classified as Category C. First trimester: No increased risk of major malformations observed in human studies; animal studies show fetal toxicity at high doses. Second and third trimesters: May cause fetal . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.